SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                  FORM 10-QSB


(Mark One)
(X)  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934

     For the quarterly period ended June 30, 2002.

( )  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

     For the transition period from ______________to_____________


                       Commission File Number 000-28311


                              HEALTHBRIDGE, INC.
            ------------------------------------------------------
     (Exact name of small business issuer as specified in its charter)

                TEXAS                                 06-1538201
            -------------                            -------------
    (State or other jurisdiction of              (IRS Employer ID No.)
     incorporation or organization)

                       1818 - 1177 West Hastings Street,
                      Vancouver, British Columbia V6E 2K3
            ------------------------------------------------------
                   (Address of principal executive office)

                                (604) 602-1717
            ------------------------------------------------------
                          (Issuer's telephone number)


Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for
such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.

                               Yes [X]   No [ ]

The number of outstanding shares of the issuer's common stock, $0.001 par value
(the only class of voting stock), as of August 13, 2002 was 18,841,346.

===============================================================================
<PAGE>
<TABLE>
                               TABLE OF CONTENTS

<S>                                                                       <C>
PART I

ITEM 1.  FINANCIAL STATEMENTS . . . . . . . . . . . . . . . . . . . . . .    3

Unaudited Consolidated Balance Sheet as of June 30, 2002  . . . . . . . .    4

Unaudited Consolidated Statement of Operations
for the three and six months ended June 30, 2002 and 2001
and the period from inception to June 30, 2002  . . . . . . . . . . . . .    5

Unaudited Consolidated Statement of Cash Flows
for the six months ended June 30, 2002 and 2001
and the period from inception to June 30, 2002 . . . . . . . . . . . . . .   6

Notes to Unaudited Financial Statements  . . . . . . . . . . . . . . . . .   7

ITEM 2.  MANAGEMENT'S PLAN OF OPERATION . . . . . . . . . . . . . . . . .    9


PART II

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K  . . . . . . . . . . . . . . . .  11

SIGNATURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  12

CERTIFICATIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  12

INDEX TO EXHIBITS  . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13

</TABLE>
                                    -  2 -
===============================================================================
<PAGE>

PART I

ITEM 1.  FINANCIAL STATEMENTS

As used herein, the term "Company" refers to Healthbridge, Inc., a Texas
corporation its subsidiaries and predecessors, unless otherwise indicated.
Unaudited interim financial statements including a balance sheet for the
Company as of the quarter ended June 30, 2002, statement of operations and
statement of cash flows for the interim period up to the date of such balance
sheet and the period since inception of the preceding year are attached hereto
as Pages 4 through 7 and are incorporated herein by this reference.


                                    -  3 -
===============================================================================
<PAGE>

                              HEALTHBRIDGE, INC.
                        (A Development Stage Company)
<TABLE>
                     UNAUDITED CONSOLIDATED BALANCE SHEET
                                JUNE 30, 2002


<S>                                                   <C>
ASSETS

Current Assets
   Cash and cash equivalents                          $     66,681
                                                      ------------
Total Current Assets                                        66,681

Intangible Assets                                          405,000
                                                      ------------

Total Assets                                          $    471,681
                                                      ============


LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities
   Accounts payable and accrued expenses              $    464,608
   Loans from shareholders                                  59,000
   Notes payable - BIME                                     69,554
   Convertible debentures                                  325,000
   Accrued Interest                                         10,814
                                                      ------------
Total Liabilities                                          928,976

Commitments and Contingencies                                 -

Stockholders' Equity
Preferred Stock:  $0.0001 Par Value,
   Authorized: 25,000,000 Issued and outstanding:
   None                                                      None
Common Stock: $0.0001 Par Value,
   Authorized Shares:  50,000,000;
   Issued and Outstanding:  18,841,346                       1,885
Additional Paid In Capital                               6,954,004
Deficit Accumulated During the Development Stage        (7,413,184)
                                                      ------------
Total Stockholders' Equity (A Deficit)                     457,295
                                                      ------------

Total Liabilities and Stockholders' Equity            $    471,681
                                                      ============

<FN>
          See condensed notes to consolidated financial statements.
</TABLE>
                                    -  4 -
===============================================================================
<PAGE>

                              HEALTHBRIDGE, INC.
                        (A Development Stage Company)
<TABLE>
               UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS
        FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2002 AND 2001, AND
      FOR THE PERIOD FROM INCEPTION (FEBRUARY 17, 1993) TO JUNE 30, 2002

<CAPTION>
                                                                                                    Deficit
                                                  Three Months               Six Months           Accumulated
                                                 Ended June 30,            Ended June 30,         During the
                                            ------------------------  ------------------------    Development
                                               2002         2001         2002         2001           Stage
                                            -----------  -----------  -----------  -----------   -------------
<S>                                         <C>          <C>          <C>          <C>           <C>
Revenues                                           -            -            -            -               -

General and administrative expenses            (324,120)    (101,279)    (964,612)    (155,947)     (2,284,002)
                                            -----------  -----------  -----------  -----------   -------------

Operating loss                                 (324,120)    (101,279)    (964,612)    (155,947)     (2,284,002)

Other Income (Expense)
  Interest expense                               (4,944)        -          (5,901)      (3,390)        (31,300)
  Interest income                                  -            -              54         -              8,563
                                            -----------  -----------  -----------  -----------   -------------
Total other income (expense)                     (4,944)        -          (5,847)      (3,390)        (22,737)
                                            -----------  -----------  -----------  -----------   -------------

Loss from continuing operations                (329,064)    (101,279)    (970,459)    (159,337)     (2,306,739)

Loss on discontinued operations                    -            -            -            -         (2,995,849)
                                            -----------  -----------  -----------  -----------   -------------

Net loss before cumulative effect
  of accounting change                         (329,064)    (101,279)    (970,459)    (159,337)     (5,302,588)

Cumulative effect of accounting change             -            -            -            -           (102,500)
                                            -----------  -----------  -----------  -----------   -------------

Net loss available to common stockholders   $  (329,064) $  (101,279) $  (970,459) $  (159,337)  $  (5,405,088)
                                            ===========  ===========  ===========  ===========   =============

Basic and diluted loss per share:
  Continuing operations                     $    (0.02)  $    (0.007) $    (0.05)  $    (0.01)
  Discontinued operations                          -            -            -            -
  Cumulative effect of accounting change           -            -            -            -
  Net loss available to common stockholders $    (0.02)  $    (0.007) $    (0.05)  $    (0.01)
                                            ===========  ===========  ===========  ===========

Basic and diluted weighted average number
  of common shares outstanding               18,535,192   13,679,851   17,750,131   13,462,568
                                            ===========  ===========  ===========  ===========

<FN>
          See condensed notes to consolidated financial statements.
</TABLE>
                                    -  5 -
===============================================================================
<PAGE>

                              HEALTHBRIDGE, INC.
                        (A Development Stage Company)
<TABLE>
               UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
             FOR THE SIX MONTHS ENDED JUNE 30, 2002 AND 2001, AND
      FOR THE PERIOD FROM INCEPTION (FEBRUARY 17, 1993) TO JUNE 30, 2002

<CAPTION>
                                                                           Less
                                                   Six Months           Accumulated
                                                 Ended June 30,         During the
                                            ------------------------    Development
                                               2002         2001           Stage
                                            -----------  -----------   -------------
<S>                                         <C>          <C>           <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss                                    $  (970,459) $   (58,058)  $  (5,405,088)
Adjustments to Reconcile Net Loss to
  Net Cash Used In Operating Activities
    Common Stock Issued for Services            702,100        3,000       1,032,250
    Compensation Cost                              -            -              6,000
    Depreciation and Amortization                  -            -             10,778
    Write-off of Organizational Costs              -            -            102,500
    Write-off of Intangible Assets                 -            -          2,100,007
    Write-off of Inventory Disposed of             -            -             40,395
Changes in Assets and Liabilities
    (Increase) Decrease in Other Advances         7,866         -               -
    Increase (Decrease) in Accounts Payable     141,963          374         460,074
    Increase (Decrease) in Accrued Interest       5,847        3,389          31,246
                                            -----------  -----------   -------------
Total Adjustments                               857,776        6,763       3,783,250
                                            -----------  -----------   -------------
Net Cash Flows Used In Operating Activities    (112,683)     (51,295)     (1,621,838)

CASH FLOWS FROM INVESTING ACTIVITIES
  Payment on intellectual property rights      (119,447)        -           (119,447)
                                            -----------  -----------   -------------
Net cash flows used in investing activities    (119,447)        -           (119,447)

Cash Flows From Financing Activities
  Loans from shareholders                        10,500       30,000         553,005
  Proceeds from secured note payable            165,000         -            165,000
  Repayment of secured note payable            (165,000)        -           (165,000)
  Notes payable-convertible debentures          325,000         -            325,000
  Proceeds from the Sale of Common Stock           -            -          1,095,000
  Offering Costs                                (47,500)        -           (168,100)
                                            -----------  -----------   -------------
Net Cash Flows Provided
  By Financing Activities                       288,000       30,000       1,804,905
                                            -----------  -----------   -------------

Increase (Decrease) in Cash and
  Cash Equivalents                               55,870      (21,295)         63,620

Cash and Cash Equivalents,
  Beginning of period                            10,811       24,623           3,061
                                            -----------  -----------   -------------

Cash and Cash Equivalents, End of period    $    66,681  $     3,328   $      66,681
                                            ===========  ===========   =============

Cash paid for interest and income taxes:           -            -               -


Supplemental noncash investing and financing activities:
  Common Stock Issued for Services          $   702,100  $     3,000   $   1,032,250
                                            ===========  ===========   =============
  Conversion of Debt and Accrued
     Interest to Equity                     $      -     $      -      $   1,499,618
                                            ===========  ===========   =============
  Conversion of Accounts Payable to Equity  $      -     $      -      $     234,500
                                            ===========  ===========   =============
  Assets Acquired for Common Stock          $   225,000  $      -      $   1,245,465
                                            ===========  ===========   =============
  Common Stock Issued as Dividends-in-kind  $      -     $      -      $   2,008,096
                                            ===========  ===========   =============

<FN>
          See condensed notes to consolidated financial statements.
</TABLE>
                                    -  6 -
===============================================================================
<PAGE>

                              HEALTHBRIDGE, INC.
                        (A Development Stage Company)

              NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
                                JUNE 30, 2002


NOTE 1.  STATEMENT OF INFORMATION FURNISHED

The accompanying unaudited interim financial statements have been prepared
in accordance with Form 10QSB instructions and in the opinion of management
contains all adjustments (consisting of only normal recurring adjustments)
necessary to present fairly the financial position as of June 30, 2002 and
the results of operations and cash flows for the three and six months ended
June 30, 2002 and 2001. These results have been determined on the basis of
generally accepted accounting principles and practices and applied consistently
with those used in the preparation of the Company's 2001 Annual Report on
Form 10-KSB.

Certain information and footnote disclosure normally included in the financial
statements presented in accordance with generally accepted accounting
principles have been condensed or omitted. It is suggested that the
accompanying financial statements be read in conjunction with the accompanying
audited financial statements and notes thereto incorporated by reference in the
Company's 2001 Annual Report on Form 10-KSB.


NOTE 2.  PRESENTATION

Certain accounts have been reclassified to confirm to the current period's
presentation. These changes had no effect on previously reported results of
operations or total stockholders' equity.


NOTE 3.  PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the accounts of Healthbridge, Inc.
(a Texas corporation) and its newly formed wholly-owned subsidiary, Healthbridge
(Deutschland) AG (a German entity).  All significant inter-company balances and
transactions have been eliminated in consolidation.


NOTE 4.  EARNINGS (LOSS) PER SHARE

Earnings (loss) per share of common stock are computed by dividing the net loss
(numerator) for the period by the weighted average number of common shares
outstanding (denominator) during the period. Diluted earnings or loss per share
are based on the weighted average number of common shares outstanding and
dilutive common stock equivalents. All per share information is adjusted
retroactively to reflect stock splits and changes in par value, when
applicable. Convertible securities that could potentially dilute basic earnings
per share in the future are not included in the computation of diluted earnings
per share because to do so would be anti-dilutive. All loss per share amounts
in the financial statements are basic earnings or (loss) per share.


NOTE 5.  GOING CONCERN, FINANCIAL RESULTS AND LIQUIDITY

To date, the Company has not been profitable. The Company faces all the risks
common to companies in their early stages of development, including
undercapitalization and uncertainty of funding sources, high initial
expenditure levels and uncertain revenue streams, an unproven business model,
and difficulties in managing growth. The Company's recurring losses raise
substantial doubt about its ability to continue as a going concern. The
Company's financial statements do not reflect any adjustments that might result
from the outcome of this uncertainty. The Company expects to incur losses as it
expands its business and will require additional funding during the next twelve
months. The satisfaction of the Company's cash requirements hereafter will
depend in large part on its ability to successfully raise capital from external
sources to fund operations. As a result, the Company expects to aggressively
pursue additional sources of funds, including debt and equity offerings.

                                    -  7 -
===============================================================================
<PAGE>

NOTE 6.  INTANGIBLE ASSETS AND NOTES PAYABLE - BIME

On January 25, 2002, the Company entered into an Intellectual Property
Assignment and Sale Agreement ("Agreement") with several parties ("Sellers")
for the purpose of acquiring certain infectious waste sterilization and
disposal technologies developed in Germany. The Agreement requires the Company
to pay to the Sellers a total of $180,000 and 750,000 restricted shares in
three installments. The total value of the intangible asset is $405,000
representing $180,000 and 750,000 shares of restricted common stock valued at
$0.30 per share representing the fair marked value on the date of issuance.
In accordance with Statement of Financial Accounting Standards No. 142,
"Goodwill and Other Intangible Assets," the Company plans to assess impairment
of the asset at least annually.  The Company also agreed to assume certain
liabilities of the sellers as part of the Agreement

As of June 30, 2002, the Company had paid US$119,447.  The remaining balance
was due in two installments of $21,000 Euros each on June 15, 2002 and
July 15, 2002.  The balance represents certain liabilities totaling 28,000
Euros assumed by the Company as part of the Agreement. The two payments
remained outstanding as of June 30, 2002. One of the payments in the amount of
21,000 Euros was paid subsequent to the end of the period. An amount of 21,000
Euros remain outstanding as of the date of this filing.

Funds used to close the Agreement were obtained from an individual unrelated
to the Company pursuant to a Secured Loan Agreement dated January 24, 2002,
for $165,000 of which $15,000 represented the fixed interest payment to the
individual as consideration for the loan. The loan was secured by the
intellectual property described above. The note was paid in full on
May 10, 2002.


NOTE 7.  CONVERTIBLE DEBENTURES

During May 2002, the Company raised $325,000 through the issuance of Series A
Convertible Debentures for a term of three years, bearing interest at 7.5% and
payable annually on the original issue date. Principal and interest are
convertible into shares of the Company's common stock during the term at a
conversion price of $0.25 per share. In the event that the trading average
price of the shares of common stock during 30 consecutive trading days is above
200% of the conversion price. The Company has agreed to file a registration
statement to register the underlying securities within 120 days of closing the
offering and to pay a 10% commission on funds raised.   During the second
quarter of 2002, the Company paid $32,500 in commission for the funds raised.

                                    -  8 -
===============================================================================
<PAGE>

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

The following discussion should be read in conjunction with the financial
statements and notes thereto included in Item 7 to the Company's most recent
Form 10-KSB. Except for the historical information contained herein, the
discussion in this Quarterly Report on Form 10-QSB contains certain forward
looking statements that involve risk and uncertainties, such as statements of
the Company's plans, objectives, expectations and intentions. The cautionary
statements made in this document should be read as being applicable to all
related forward-looking statements wherever they appear in this document.
The Company's actual results could differ materially from those discussed
here. The Company is a development stage company that is engaged in the
marketing and distribution of infectious medical waste sterilization and
disposal technologies. To date, management has devoted the majority of efforts
to (i) negotiating and concluding a technology purchase agreement,
(ii) developing its marketing philosophy and market strategy, including
registering patents throughout the world, (iii) pursuing and assembling a
management team to complete its marketing goals, (iii) obtaining sufficient
working capital through loans from shareholders, equity and debt offerings to
conclude the technology acquisition; and negotiating joint venture agreements
to commercialize the technologies.

PLAN OF OPERATION

The Company's plan of operation is to manufacture, and market the
Valides(r) and Medides Systems medical waste sterilization and disposal
technologies to the international market for medical waste disposal.

During the second quarter of the current fiscal year, the Company has
identified markets for the Valides(r) and Medides Systems in Europe, South
America and Asia. The Company's activities in Europe included initiating
the hiring process for fabrication and production staff and identifying
a production site. The focus outside of Europe during the second quarter
was to identify potential production sites and form alliances to expand
the Company's sales network.

The third quarter of the current fiscal year is to be devoted to building on
the Company's activities in Europe and expanding operations to South American
markets. The Company expects to file applications with South American
regulatory bodies that would introduce the Valides(r) and Medides Systems to
South America, hire a manager and fabricator in South America.
Further, the Company is in the process of concluding a distributorship
agreements in Brazil and Taiwan.

The Company expects to expand its activities into Asian markets in the fourth
quarter of the current fiscal year while growing operations in Europe and South
America through joint venture arrangements. Management intends to file
applications with Asian regulatory bodies in an effort to introduce the
Valides(r) and Medides Systems to Asian markets. The Company's pattern of
expansion would include expanding its sales force, hiring a manager. The
Company anticipates purchase orders from Asia this year.

LIQUIDITY AND CAPITAL RESOURCES

As of June 30, 2002, the Company's only significant asset was intangible assets
of $405,000 representing the intellectual property rights to the Valides(r) and
Medides Systems.

                                    -  9 -
===============================================================================
<PAGE>

The Company intends to raise up to $1,000,000 through convertible debentures
with three year terms bearing interest at 7.5% convertible into shares of
the Company's common stock at a conversion price of $0.25 per share to fund
the plan of operation through the calendar year ending December 31, 2002.
During the first six months of 2002, the Company raised $325,000 in convertible
debentures and $165,000 through a secured note payable.  The funds were used
as follows:  repaid the secured loan of $165,000, approximately $64,000 was
advanced to the Company's newly formed German subsidiary for working capital
and incorporation, $47,500 was paid in commissions for capital raising during
2002, and approximately $120,000 was paid for the purchase of the intellectual
property rights.

Should the Company be unable to successfully complete the convertible
debenture offering, it anticipates raising capital through other debt or
equity financings from public or private sources to satisfy the cash needs
of fulfilling its plan of operation through the calendar year ending
December 31, 2002. However, there can be no assurances that the Company
will be able to raise the funds required by its plan of operation.

The Company intends to purchase equipment to be used in the production of
the Valides(r) and Medides Systems as described in its plan of operation.
The intention to purchase equipment is subject to the Company's ability to
raise sufficient capital to satisfy its plan of operation.

The Company intends to hire new employees as managers, production personnel
and sales people in accord with its plan of operation. The intention to hire
employees is subject to the Company's ability to raise sufficient capital to
satisfy its plan of operation.

CRITICAL ACCOUNTING POLICIES

The financial statements were prepared in accordance with accounting principles
generally accepted in the United States, which requires management to make
estimates and judgments that affect the reported amounts of assets,
liabilities, revenues and expenses, and related disclosure of contingent assets
and liabilities. On an on-going basis, the Company evaluates its estimates,
including those related to intangible assets and bases its estimates on various
assumptions that are believed to be reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources.
Actual results may differ from these estimates under different assumptions or
conditions.

The Company believes that its accounting policy for intangible assets to be
its only critical accounting policy because it is primarily based on the asset
generating future cash flows.  The Company periodically evaluates whether
events and circumstances have occurred that may warrant revision to the
remaining balance of the intangible asset due to possible impairment. If and
when such factors, events or circumstances indicate that the intangible asset
should be evaluated for possible impairment, the Company would make an estimate
of undiscounted cash flows over the remaining lives of the respective assets in
measuring recoverability.  Judgment is required in assessing the realization of
any future economic benefits resulting from the carrying value of the assets.
Fluctuations in the actual outcome of these future economic benefits could
materially impact the Company's financial position or its results of
operations.  In the event that the Company did not generate any future economic
benefit as a result of the carrying value of the related assets, total assets
would be overstated by approximately $405,000.  Reducing the assets to zero
would result in an additional expense in the period in which it is determined
that the asset cannot be realized.  These assets represent approximately 86% of
our total assets at June 30, 2002.

                                    - 10 -
===============================================================================
<PAGE>

RECENT ACCOUNTING PRONOUNCEMENTS

In June 2002, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standards ("SFAS") No. 146, "Accounting for
Costs Associated with Exit or Disposal Activities," effective for exit or
disposal activities initiated after December 31, 2002.  The standard addresses
financial accounting and reporting for costs associated with exit or disposal
activities and nullifies Emerging Issues Task Force ("EITF") No. 94-3,
"Liability Recognition for Certain Employee Termination Benefits and Other
Costs to Exit an Activity."  SFAS 146 essentially requires a liability to be
recognized and measured initially at its fair value in the period in which the
liability is incurred for a cost associated with an exit or disposal activity.
The Company has not had a chance to review what impact this standard may have
on its financial statements.


                                   PART II


ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

         (a)  EXHIBITS.  Exhibits required to be attached by Item 601 of
              Regulation S-B are listed in the Index to Exhibits on page 14
              of this Form 10-QSB, and are incorporated herein by this
              reference.

         (b)  REPORTS ON FORM 8-K.  None.



                                    - 11 -
===============================================================================
<PAGE>


                                  SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized, this 14th day of August, 2002.


HEALTHBRIDGE, INC.


________________________________________________
Nora Coccaro
President, Chief Financial Officer, and Director




         CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
           SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of Healthbridge, Inc. on Form 10-Q
for the period ending June 30, 2002 as filed with the Securities and Exchange
Commission on the date hereof, Nora Coccaro, as Chief Executive/Financial
Officer of Healthbridge, Inc., does hereby certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that to the best of her knowledge:

     1.   This 10-QSB report fully complies with the requirements of
          Section 13(a) of the Exchange Act; and

     2.   The information contained in this 10-QSB report fairly presents,
          in all material respects, the financial condition and result of
          operations of Healthbridge, Inc..




_____________________________________
Nora Coccaro
Chief Executive and Financial Officer
August 14, 2002




                                    - 12 -
===============================================================================
<PAGE>


                              INDEX TO EXHIBITS


EXHIBIT      PAGE
NO.          NO.          DESCRIPTION
-------      ----     ---------------------------------------------------------
 3(i)         *       Articles of Incorporation of the Company
 3(ii)        *       Amendment to Articles of Incorporation of the Company
 3(iii)       *       Amendment to Articles of Incorporation of the Company
 3(iv)        *       Amended and Restated Articles of Incorporation of the
                      Company
 3(v)         *       Bylaws of the Company

  *       Incorporated by reference from the 10-SB filed with the
          Commission on April 17, 2000

                                    - 13 -
===============================================================================
<PAGE>